A young person can be forgiven for feeling out of control when everything—their body, brain, hormones, interests, perspectives, identity, and relationships—are all changing. The people around them are ...

Attention-Deficit Hyperactivity Disorder (ADHD) has as its core symptoms hyperactivity (which mostly applies to children), impulsivity and inattention (distractibility). Across the timeline, much of ...

Young adults diagnosed with attention deficit/hyperactivity disorder (ADHD) in adolescence show differences in brain structure and perform poorly in memory tests compared to their peers, according to ...

Experts weigh in on why kids with ADHD sleep less and with more disruptions to their sleep cycle.

Adolescent Patients With ADHD Pose Special Challenges to Their Families Since adolescence is a period of great growth and development, adolescents with ADHD pose special challenges to their families.

The FDA has approved Simtriyo, a nonstimulant daily pill for ADHD in children, teens, and adults. Here’s more on potential ...

Increased public awareness of ADHD, better diagnostic care and the availability of new and improved medications may all ...

ADHD likely affects more than 5% of children and early adolescents worldwide. Over several decades, neurologists have identified a strong link between ADHD symptoms and deficits in omega-3, which is ...

Yvette C. Terrie, RPh, BS Pharm, discusses the clinical potential of the first triple reuptake inhibitor for ADHD.

They found a significant downward trend in ADHD incidence among adults from 2016 to 2020 and an upward trend from 2020 to 2023. Among adolescents, a significant downward trend was observed between ...

In the UK, healthcare for children with ADHD is usually provided by either paediatric services or by CAMHS, depending on local arrangements. There are good examples of joint working in some regions, ...

Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and serotonin, promising fewer side effects.